Department of Pediatrics, Division of Medical Genetics, and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94115; email:
Annu Rev Genomics Hum Genet. 2013;14:355-69. doi: 10.1146/annurev-genom-091212-153523. Epub 2013 Jul 15.
The RASopathies are a clinically defined group of medical genetic syndromes caused by germline mutations in genes that encode components or regulators of the Ras/mitogen-activated protein kinase (MAPK) pathway. These disorders include neurofibromatosis type 1, Noonan syndrome, Noonan syndrome with multiple lentigines, capillary malformation-arteriovenous malformation syndrome, Costello syndrome, cardio-facio-cutaneous syndrome, and Legius syndrome. Because of the common underlying Ras/MAPK pathway dysregulation, the RASopathies exhibit numerous overlapping phenotypic features. The Ras/MAPK pathway plays an essential role in regulating the cell cycle and cellular growth, differentiation, and senescence, all of which are critical to normal development. Therefore, it is not surprising that Ras/MAPK pathway dysregulation has profound deleterious effects on both embryonic and later stages of development. The Ras/MAPK pathway has been well studied in cancer and is an attractive target for small-molecule inhibition to treat various malignancies. The use of these molecules to ameliorate developmental defects in the RASopathies is under consideration.
RAS 相关疾病是一组临床上定义明确的遗传性疾病,由 Ras/丝裂原活化蛋白激酶(MAPK)途径编码组件或调节剂的种系突变引起。这些疾病包括神经纤维瘤病 1 型、努南综合征、多发性痣努南综合征、毛细血管畸形-动静脉畸形综合征、科斯特洛综合征、心面四肢综合征和莱格斯综合征。由于共同的 Ras/MAPK 途径失调,RAS 相关疾病表现出许多重叠的表型特征。Ras/MAPK 途径在调节细胞周期和细胞生长、分化和衰老方面起着至关重要的作用,这些都是正常发育所必需的。因此,Ras/MAPK 途径失调对胚胎和发育后期都有深远的有害影响并不奇怪。Ras/MAPK 途径在癌症中得到了很好的研究,是小分子抑制的一个有吸引力的靶点,用于治疗各种恶性肿瘤。正在考虑使用这些分子来改善 RAS 相关疾病的发育缺陷。